 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- SPG302 / Spinogenix
Novel Regenerative Drug, SPG302 Promotes Functional Recovery of Diaphragm Muscle Activity After Cervical Spinal Cord Injury (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_4742;
Treatment with SPG302 also ameliorated Pdi deficits following C2SH, with ~36% improvement compared to vehicle treatment during eupnea, ~40% during HH, ~25% during occlusion and ~14% during maximum Pdi. In summary, SPG302 is an exciting new therapeutic option for use to promote recovery after spinal cord injuries.
- ||| SPG302 / Spinogenix
Enrollment open: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302 in Healthy Volunteers and ALS Participants (clinicaltrials.gov) - Jul 10, 2023
P1, N=112, Recruiting, Sponsor: Spinogenix
In summary, SPG302 is an exciting new therapeutic option for use to promote recovery after spinal cord injuries. Not yet recruiting --> Recruiting
- | SPG302 / Spinogenix
Journal: Novel regenerative drug, SPG302 promotes functional recovery of diaphragm muscle activity after cervical spinal cord injury. (Pubmed Central) - Jun 16, 2023
C SH depressed P , with SPG302 having improved P compared to vehicle treated. In conclusion, SPG302 presents a promising potential therapeutic for use in spinal cord injury.
- | SPG302 / Spinogenix
New P1 trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302 in Healthy Volunteers and ALS Participants (clinicaltrials.gov) - May 31, 2023
P1, N=112, Not yet recruiting, Sponsor: Spinogenix
- | SPG302 / Spinogenix
Journal: SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer's Disease. (Pubmed Central) - Mar 31, 2022
Notably, SPG302 proved efficacious in this model without modifying Aβ and tau pathology. Thus, our study provides preclinical support for the idea that compounds capable of restoring synaptic density offer a viable strategy to reverse cognitive decline in AD.